Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic

Current Research in Pharmacology and Drug Discovery(2022)10.1016/j.crphar.2022.100101Source: DataRank Database

The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic is a research paper published in Current Research in Pharmacology and Drug Discovery (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

gen doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.85)OA: goldTopics (29)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Erica J. Brenner ORCID,Chethana Kamath ORCID

Live enrichment

PubMed:35496814 PMC:PMC9040409 OpenAlex:https://openalex.org/W4224929091

National Institutes of Health

Grant: T32 DK007634

National Institutes of Health

Grant: 5T32DK007634-21

Digestive Disease Epidemiology Training Program

FWCI

0.85

Citation Percentile

0.7%

Citation Trend

2022

2023

2025

2026

goldLicense: cc-by

journalhttps://www.sciencedirect.com/science/article/pii/S2590257122000219/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2590257122000219/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2590257122000219?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2590257122000219?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.crphar.2022.100101

Fields of Study

Inflammatory Bowel DiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research03 medical and health sciences0302 clinical medicine

Keywords

MedicineInflammatory bowel diseasePandemicCoronavirus disease 2019 (COVID-19)Intensive care medicineDiseaseInternal medicineInfectious disease (medical specialty)Tnf, Tumor Necrosis FactorCi, Confidence IntervalIbd, Inflammatory Bowel DiseaseUc, Ulcerative ColitisMtx, MethotrexateAor, Adjusted Odds RatioCovid-19, Coronavirus Disease 20195-Asa, 5-AminosalicylatesAga, American Gastrointestinal AssociationIcu, IlJak, Janus Kinase InhibitorSecure-ibd, Surveillance Epidemiology Of Coronavirus Under Research Exclusion For Inflammatory Bowel DiseaseInterleukin, Intensive Care UnitTherapeutics. PharmacologyRM1-950Review Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic

FAIR Checklist

Authors (2)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)